New Drug Targets Mutant HER2

This is a Bangalore news story, published by Interesting Engineering, that relates primarily to HER2 news.

Bangalore news

For more Bangalore news, you can click here:

more Bangalore news

HER2 news

For more HER2 news, you can click here:

more HER2 news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Interesting Engineering news

For more news from Interesting Engineering, you can click here:

more news from Interesting Engineering

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

mutant HER2 cancer cells

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest mutant cancer protein news, HER2 mutations news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

mutant HER2 tumors

Interesting Engineering

•

NYU’s new drug attacks cancer mutations while protecting healthy cells

Summary

Nutrition label

81% Informative

Researchers at NYU Langone Health developed a drug that targets a mutant cancer protein called HER2 without attacking its nearly identical normal counterpart on healthy cells.

The treatment significantly reduced tumor growth when the researchers tested their T cell engagers in mice with mutant HER2 tumors.

The researchers say this technique could lead to new therapies to treat cancer patients with HER2 mutations with minimal side effects.

Kapil holds a dual bachelor's degree in Electrical, Electronics , and Communication Engineering and a master’s diploma in journalism from the Institute of Journalism and New Media in Bangalore .

His work has been featured in publications such as National Geographic , Al Jazeera , Rest of World , Mongabay , and Nikkei.

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language

not offensive

Hate speech